Still betting on Nvidia? Our AI picked this stock instead; it’s up 96%+ THIS MONTH
Jennifer Doudna, a director at Tempus AI , Inc. (NASDAQ:TEM), recently sold shares in the company amounting to $454,210. According to InvestingPro data, TEM currently trades at $48.03, with the stock showing mixed performance - down in the past month but delivering a solid 42% return year-to-date. The transactions occurred on March 17, 2025, and involved the sale of 9,308 shares of Class A Common Stock. The shares were sold at prices ranging from $46.67 to $50.63. After these transactions, Doudna holds 26,365 shares in the company. The sale comes as Tempus AI, with a market capitalization of $7.9 billion, maintains strong liquidity with a current ratio of 2.29, though InvestingPro analysis indicates the stock is currently trading above its Fair Value. These sales were conducted under a pre-arranged 10b5-1 trading plan, which Doudna adopted in August 2024. While the company shows moderate debt levels and strong liquid assets, investors should note that InvestingPro carries 7 additional key insights about Tempus AI’s financial health and market position in its comprehensive Pro Research Report.
In other recent news, Tempus AI reported a 35.8% increase in fourth-quarter revenue for 2024, reaching $700 million. The earnings per share were -0.18, which may have influenced investor sentiment negatively. The company has also increased its 2025 revenue guidance to approximately $1.24 billion, surpassing previous estimates. This forecast includes contributions from Ambry Genetics, which Tempus AI acquired earlier this year. In a strategic move, Tempus AI also acquired Deep 6 AI to enhance its capabilities in AI-driven research platforms, particularly in streamlining clinical trials.
JPMorgan downgraded Tempus AI’s stock from Overweight to Neutral, despite raising the price target to $55, citing a fully valued stock relative to peers. On the other hand, Stifel maintained a Hold rating with a $65 price target, aligning with consensus estimates of a 30% growth in core revenue for the fiscal year 2025. Tempus AI launched the Olivia AI personal health app, further expanding its product offerings. These developments reflect Tempus AI’s continued growth and strategic positioning in the healthcare technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.